ProMIS Neurosciences Inc PMN

No News

[goldtech]

This company has never ever had the stock acumen needed to attract shareholder appreciation and awareness. Wake up management!!!!!

[G1945V]

What is important about bringing Acumen to the discussion is that we now know that Acumen also binds plaque attributing to the ERIA-E-related brain swelling side effects. However, we don't know for sure if PMN-310 only binds to toxic oligomers. We'll know for sure in Phase 1b in mid-2025 as I understand it.  G1945V

[garygp]

I think goldtech was meaning more along the lines of business acumen, meaning the ability of management to think quickly, ability to make sound business decisions and act on them, and not Acumen Pharmaceuticals.   If I understand my interpretations correctly/context, then goldtech is correct in spades.

[M101]

Perhaps Goldtech will enlighten us all as to what a winning argument might be for such a hypothetically endowed company? 

[M101]

And btw, I don't think they have anything to lose by attacking big pharma on multiple fronts. Money has no feelings. 

[Gbathat]

PMN310 stands out from the competition in vitro.   The original Acumen publication cited some anomalies for non-target binding to plaque, and I always thought it was strange that those statements got through the peer review process. When tested in PMN's lab, it is pretty clear ACU binds significantly to plaque, whereas PMN310 does not.  Again, in vitro.  The clinic will

[G1945V]

Hoping for a lower dose of PMN-310 to be successful enough that could lead to subcutaneous (injection) dosing of AZ patients in place of intravenous. Makes it easier for patients and presumable less costly. (Big plus)   G1945V